甲磺酸贝舒地尔治疗慢性移植物抗宿主病临床应用指导原则(2024年版)
Guidelines for clinical application of belumosudil mesylate in treatment of chronic graft-versus-host disease(2024 version)
中国临床肿瘤学会(CSCO)白血病专家委员会 马军 1吴德沛2
作者信息
- 1. 哈尔滨血液病肿瘤研究所,哈尔滨 150010
- 2. 苏州大学附属第一医院血液科,苏州215006
- 折叠
摘要
甲磺酸贝舒地尔是一种口服的选择性Rho相关卷曲螺旋蛋白激酶2(ROCK2)抑制剂,临床研究证实其治疗慢性移植物抗宿主病(cGVHD)患者具有良好的效果和安全性.2021年7月,美国食品药品监督管理局(FDA)批准甲磺酸贝舒地尔用于既往至少接受过2线系统性治疗失败后的cGVHD成年患者和≥12岁的儿童患者.2023年8月,甲磺酸贝舒地尔在我国获批用于治疗对糖皮质激素或其他系统治疗应答不充分的≥12岁cGVHD患者.鉴于上市之初临床医生用药经验尚不丰富,中国临床肿瘤学会(CSCO)白血病专家委员会牵头制定了甲磺酸贝舒地尔治疗cGVHD临床应用指导原则,旨在为我国临床医生提供用药参考.
Abstract
Belumosudil mesylate is an oral selective Rho-associated coiled-coil-containing protein kinase 2(ROCK2)inhibitor,which has shown promising efficacy and safety in the treatment of patients with chronic graft-versus-host disease(cGVHD),as confirmed by clinical studies.In July 2021,the U.S.Food and Drug Administration(FDA)approved belumosudil mesylate for adult and pediatric patients aged 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy.In August 2023,belumosudil mesylate was approved in China for the treatment of cGVHD in patients aged 12 years and older who have inadequate response to glucocorticoids or other systemic therapies.In view of the lack of clinicians'medication experience at the beginning of marketing,Leukemia Expert Committee of Chinese Society of Clinical Oncology(CSCO)led to formulate the guiding principles for clinical application of belumosudil mesylate in the treatment of cGVHD,aiming to provide medication references for Chinese clinicians.
关键词
慢性移植物抗宿主病/甲磺酸贝舒地尔/治疗结果Key words
Chronic graft-versus-host disease/Belumosudil mesylate/Treatment outcome引用本文复制引用
出版年
2024
NETL
NSTL
万方数据